Prestige Biologics Company Description

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars.

Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors.

Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019.

The company was founded in 2015 and is based in Cheongju-si, South Korea.

Prestige Biologics Co., Ltd.

Country	South Korea
Founded	2015
Industry	Biological Products, Except Diagnostic Substances

Contact Details

Address: 197, Osongsaengmyeong 1-ro Cheongju-Si, 28161 South Korea
Phone	82 4 3232 1552
Website	pbpharma.co.kr

Stock Details

Ticker Symbol	334970
Exchange	KOSDAQ
Fiscal Year	July - June
Reporting Currency	KRW
SIC Code	2836